Učitavanje...
Dapagliflozin: A Review in Type 2 Diabetes
Dapagliflozin (Forxiga(®)) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) a...
Spremljeno u:
| Izdano u: | Drugs |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6879440/ https://ncbi.nlm.nih.gov/pubmed/31236801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01148-3 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|